Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cancer vaccine (AlloStim) - Immunovative Therapies

Drug Profile

Cancer vaccine (AlloStim) - Immunovative Therapies

Alternative Names: AlloStim; AlloStim-7; AlloStim-8; AlloStim-9; Bioengineered allogeneic immune cells (AlloStim); InSituStim; InSituVax; Intentionally mis-matched, allogeneic Th1 memory Cells (AlloStim) conjugated With CD3/CD28-coated microbeads; Mis-matched immune cell therapy (AlloStim) - Immunovative Therapies; Personalized anti-tumour vaccine - Immunovative Therapies; StimVax®

Latest Information Update: 14 Dec 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immunovative Therapies
  • Class Cancer vaccines; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Colorectal cancer
  • Phase I/II Solid tumours
  • No development reported Haematological malignancies

Most Recent Events

  • 10 Dec 2018 Immunovative Therapies plans a phase IIb trial for Liver cancer (Metastatic disease, Late-stage disease) in South-East Asia
  • 07 Nov 2016 Phase-II clinical trials in Colorectal cancer (Metastatic disease, Second-line therapy or greater) in USA (Intradermal)
  • 07 Nov 2016 Phase-II clinical trials in Colorectal cancer (Metastatic disease, Second-line therapy or greater) in USA (Intratumoural)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top